INtraprocedural Feedback-Optimized Renal Denervation Based on Measurements Obtained Through Renal Artery Stimulation: a Randomized Controlled Trial (INFORM)

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Taiwan University Hospital

About this trial

Our previous study (Huang HC, Pan HY, Wang TD, Circ Cardiovasc Interv 2023;16:e012779) demonstrated that when renal artery stimulation continues to trigger systolic blood pressure increases (\>=20 mmHg increase compared to baseline) after the initial procedure, patients show poor blood pressure reduction 6 months following renal denervation. Based on this finding, we designed a proof-of-concept trial comparing two approaches: a guided strategy versus conventional renal denervation. In the guided strategy, we perform additional ablations of main and/or branch renal arteries if immediate post-procedure stimulation still elevates systolic blood pressure (\>=20 mmHg increase compared to baseline). The conventional approach involves no repeat procedures. This trial aims to determine whether the guided strategy leads to better clinical outcomes, measured by 6-month ambulatory blood pressure changes, and to establish the value of using intraprocedural feedback to assess and guide renal denervation treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with hypertension and are willing to undergo renal denervation.

Patients are treated with antihypertensive medications, or with an office systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg, and 24-hour SBP of >130 mmHg or DBP >80 mm Hg, irrespective of antihypertensive treatment.

Disqualifiers

An unsuitable renal artery anatomy for renal denervation, assessed by computed tomographic angiography (main renal artery lumen diameter <3 mm or a total length <20 mm).

Secondary hypertension, including hyperaldosteronism, pheochromocytoma, and renal artery stenosis (>50% stenosis in one or both arteries).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Radiofrequency ablation alone, re-denervation to main and/or branch renal artery

    Device

    Re-denervation according to the site where renal artery stimulation can induce systolic blood pressure rise of \>= 20 mmHg. Main renal artery denervation if proximal main renal artery stimulation positive, while branch renal artery denervation if distal main renal artery stimulation positive.

  • Radiofrequency ablation alone, no further renal denervation

    Procedure/Surgery

    No further renal denervation after standard renal denervation even renal artery stimulation-induced systolic blood pressure rise \>= 20 mmHg

Treatment groups

32 Participants
are divided into 3 treatment groups
Group A: A: Renal artery stimulation-induced systolic blood pressure rise suppressed (<20 mmHg)No intervention 0 interventions
Group B: B: Re-denervation if renal artery stimulation-induced systolic blood pressure rise not suppressedActive comparator 1 intervention
Group C: C: Control if renal artery stimulation-induced systolic blood pressure rise not suppressedPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

24-hour systolic blood pressure reduction (compared to baseline)

Time frame
6 months following the index renal denervation

Secondary outcomes

1

24-hour diastolic blood pressure reduction (compared to baseline)

Time frame
6 months following the index renal denervation
2

Awake and asleep systolic/diastolic blood pressure and heart rate changes (compared to baseline)

Time frame
6 months following the index renal denervation
3

Serum creatinine and estimated glomerular filtration rate changes

Time frame
6 months following the index renal denervation

Other outcomes

1

24-hour blood pressure changes based on branch artery constriction following renal artery stimulation

Time frame
6 months following the index renal denervation
2

24-hour blood pressure reduction (compared to baseline)

Time frame
1 year and 2 years following the index renal denervation

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

National Taiwan University Hospital

Lead sponsor

Smart Health Technology Research and Development Center, National Taiwan University

Collaborator

Medtronic

Collaborator